Regeneron Pharmaceuticals

Healthcare | Biotechnology | USA

Regeneron (REGN) Q4 Earnings and Revenues Surpass Estimates

Regeneron (REGN) came out with quarterly earnings of $6.84 per share, beating the Zacks Consensus Estimate of $5.69 per share. This compares to earnings of $5.23 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 20.21%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $5.21 per share when it actually produced earnings of $5.87, delivering a surprise of 12.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

...

https://finance.yahoo.com/news/regeneron...12807.html

Regeneron Earnings: Slammed On Costs, Cancer Setback — Shares Dive

...

Regeneron Earnings, Sales Miss Estimates
For the first quarter ended March 31, adjusted Regeneron earnings slipped 5% to $4.45 per share. That lagged the average estimate of analysts polled by Zacks Investment Research for Regeneron earnings of $5.52 per share.

Sales advanced 13% to $1.71 billion, but missed estimates for $1.74 billion.

"This negative result was largely anticipated after Sanofi, on April 26, reported lower collaboration antibody revenues than previously anticipated by Regeneron consensus, but was exacerbated by higher product costs and R&D spend in the quarter," Leerink's Porges said.

...

https://www.investors.com/news/technolog...yptr=yahoo

Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid

...

Regeneron reported earnings of $6.02 per share in the second quarter, beating the Zacks Consensus Estimate of $5.42. The top line also increased from $5.45 in the year-ago quarter.

Total revenues in the reported quarter increased 20% year over year to $1.93 billion and comfortably beat the Zacks Consensus Estimate of $1.80 billion. The year-over-year growth was driven by strong Eylea and Dupixent sales.


...

https://finance.yahoo.com/news/regeneron...05493.html

Regeneron ist bald ready für Tests für Corona-Impfung

vorbörslich zur Zeit um die +10%

https://www.cnbc.com/2020/03/17/regenero...ummer.html

https://finance.yahoo.com/quote/REGN?p=REGN

Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected results for the first quarter of 2020, wherein both earnings and sales beat estimates.

Shares are up in pre-market trading on strong results. Shares of Regeneron have gained 44.3% in the year so far compared with the industry’s growth of 1.7%.


...

The company reported earnings of $6.60 per share in the first quarter, comfortably beating the Zacks Consensus Estimate of $5.73 and increasing from $4.45 in the year-ago quarter.

Total revenues in the reported quarter jumped 33% year over year to $1.8 billion and comfortably beat the Zacks Consensus Estimate of $1.7 billion. However, revenues were down sequentially from $2.2 billion.  The year-over-year growth was driven by strong Eylea and Dupixent sales.


...

https://finance.yahoo.com/news/regeneron...01588.html

Nach Einschätzung des renommierten Epidemiologen Anthony Fauci könnte ein noch experimentelles Antikörper-Mittel einen entscheidenden Beitrag dazu geleistet haben, dass US-Präsident Donald Trump nach seiner Corona-Infektion das Krankenhaus wieder verlassen konnte. Sein Gesundheitszustand habe sich schnell verbessert. "Ich habe einen starken Verdacht, dass ihm das geholfen hat", sagte Fauci im Nachrichtensender CNN über das Mittel. Es war von der Biotech-Firma Regeneron auf Anfrage der Präsidenten-Ärzte bereitgestellt worden. Es wird für gewöhnliche Patienten noch lange nicht verfügbar sein.

https://www.pmlive.com/pharma_news/regen...il_1352961

Syst. Thera.

https://seekingalpha.com/news/3622868-eu...s-dupixent

Die Regeneron-Aktie konnte zuletzt eine überzeugende Performance auf das Parkett zaubern. Bei dieser Erholung wurde das Kursziel aus der letzten Chartbesprechung erreicht und der Biotechtitel steht nun an der dominanten Abwärtstrendlinie



https://www.godmode-trader.de/analyse/re...ht,9370321